LR19024

LR19024 is an investigational small molecule drug candidate currently in preclinical development by LG Chem for the treatment of osteoarthritis. It is being developed as a potential disease-modifying osteoarthritis drug (DMOAD), a class of therapeutics intended to alter the underlying pathophysiology of the disease rather than merely providing symptomatic pain relief. The program focuses on addressing cartilage degradation and joint inflammation to preserve joint structure and function. While the specific molecular target has not been publicly disclosed by the sponsor, LR19024 represents a key asset in LG Chem's musculoskeletal and immunology pipeline.